(Q44518151)

English

Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis

scientific article published in November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

0 references

Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Stanley B Cohen

1

object named as

Stanley Cohen

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Sebastião C Radominski

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Juan J Gomez-Reino

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Lisy Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sriram Krishnaswami

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Susan P Wood

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Koshika Soma

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Chudi I Nduaka

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Kenneth Kwok

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Hernan Valdez

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Birgitta Benda

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Richard Riese

12

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

2924-2937

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Predictors of infection in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Integrated safety in tocilizumab clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Induction and regulation of IFNs during viral infections

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists

1 reference

https://api.crossref.org/works/10.1002%2FART.38779

21 January 2018

Identifiers

10.1002/ART.38779

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44518151&oldid=2026610296"